share_log

香雪制药(300147.SZ):TAEST16001注射液新增适应症申报临床试验获得受理

Xiangxue Pharmaceutical (300147.SZ): The clinical trial of TAEST16001 injection with a new indication was accepted

Gelonghui Finance ·  Feb 7 03:39

Gelonghui, Feb. 7, 丨 Xiangxue Pharmaceutical (300147.SZ) announced that recently, Xiangxue Life Science Technology (Guangdong) Co., Ltd. (“Xiangxue Life Science”), a subsidiary of Guangzhou Xiangxue Pharmaceutical Co., Ltd., submitted an application for clinical registration of new indications of TAEST16001 injection to the State Drug Administration and received the “Notice of Acceptance” (acceptance number: CXSL2400103) approved and issued by the China Drug Administration.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment